Manufacture and sell a wide range of pharmaceutical products for human health. Now — the numbers.
This is an established company with proven profits.
An average decline of 5% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $1.1B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 5.9× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 24% — that slice of every sale is the company’s cushion in hard quarters.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 4 years, sales fell about 5% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.